Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Increased flux of glucose through glycolysis is a hallmark of inflammatory macrophages and is essential for optimal effector functions. Solute carrier (SLC) 37A2 is an endoplasmic reticulum-anchored phosphate-linked glucose-6-phosphate transporter that is highly expressed in macrophages and neutrophils. We demonstrate that
SLC37A2
plays a pivotal role in murine macrophage inflammatory activation and cellular metabolic rewiring. Toll-like receptor (TLR) 4 stimulation by
lipopolysaccharide
(
LPS
) rapidly increases macrophage SLC37A2 protein expression.
SLC37A2
deletion reprograms macrophages to a hyper-glycolytic process and accelerates
LPS
-induced inflammatory cytokine production, which partially depends on nicotinamide adenine dinucleotide (NAD
+
) biosynthesis. Blockade of glycolysis normalizes the differential expression of pro-inflammatory cytokines between control and
SLC37A2
deficient macrophages. Conversely, overexpression of
SLC37A2
lowers macrophage glycolysis and significantly reduces
LPS
-induced pro-inflammatory cytokine expression. In conclusion, our study suggests that
SLC37A2
dampens murine macrophage inflammation by down-regulating glycolytic reprogramming as a part of macrophage negative feedback system to curtail acute innate activation.
...
PMID:Solute Carrier Family 37 Member 2 (SLC37A2) Negatively Regulates Murine Macrophage Inflammation by Controlling Glycolysis. 3242 62